在世界艾滋病日，抗艾滋病团体亚洲TREAT公开表示，接受HIV治疗的亚洲青少年患者显示出骨质疏松的早期迹象，仅5岁的患儿就对艾滋病药物耐药，以此敦促给予年轻的HIV患者更多的关注。
这一发现提醒人们，虽然越来越多的HIV亚洲患者能得到基本的艾滋病药物，但他们得不到改进的药物，包括成人和儿童在内的患者仍然缺乏关心。
根据联合国儿童基金会，亚洲约有16万名儿童感染了HIV病毒。其中，5.7万患儿需要治疗，但至2008年底只有3万患儿得到治疗。
该团体研究者发现，仅5岁的患儿就逐渐开始对艾滋病药物耐药，可能很快就需要改进的、更昂贵的药物，但他们却得不到。
该团体的负责人Annette Sohn博士表示，在他们研究的人群中，约14%的患儿得不到一线药物，一些不到五岁的患儿就已经开始用二线药物。
服用艾滋病药物不守时或不规律会导致耐药。但在亚洲，耐药的另一原因是缺乏患儿专用的药物制剂。
Sohn博士称，在HIV流行开始大家都犯了如何管理HIV患者的错误，患儿使用的是成人制剂，亚洲国家的患儿没有儿科制剂。
Sohn博士还称，健康专家和制药商需要找办法制备药力更强大的三线药物，提供给贫穷国家的患儿。这些药物在富裕国家可得到或得到补贴，但却非常昂贵，有时在发展中国家无法得到。要不开发三线药物，那么医院里将只会剩下一无所有的患者，而医生也没有药可开给患者。
该团体对4000名23岁以下的亚洲艾滋病患者的长期研究显示，骨矿物质密度低的HIV青少年患者的比率高，这是骨质疏松的前兆。
给这些约16岁的青少年患者做了特别的X射线，发现他们中有15%骨量低。这很不正常，因为16岁青少年不应该骨量低，骨量低是因为HIV对患者的身体，包括大脑、骨、免疫系统产生影响。
Sohn博士是HIV/AIDS患儿的儿科专家，他认为这还可能是由于一些艾滋病药物，如替诺福韦，对骨的毒性作用。
问题并不是不使用一或两种药物，而是要注意它们共同的副作用，研究药物用何剂量才不会既抑制病毒又不产生毒性，有资源来监测副作用，并且有途径在产生副作用时换药。
这项研究包括泰国、越南、马来西亚、柬埔寨、印度尼西亚和印度。TREAT Asia是诊所、医院和研究机构共同致力于改进治疗途径的网络团体。
艾滋病不治会早死，早治才康复 艾滋病不治会早死，早治才康复 艾滋病不治会早死，早治才康复 艾滋病不治会早死，早治才康复
 |
| 图示∶2011年5月正式出版的《中国特色医疗金鉴》登载的刘君主任及其机构事迹 |
| |
|
|
艾滋病新鸡尾酒疗法 附 HIV感染者，早吃药早受益
Asian HIV patients taking AIDS drugs worrying
The whole network release :2011 -12-07 10:32 by: Feng Zhihong 2011-12-6 0:00
Edit: Jia Chaojuan Global Medical Network
Keywords: Jilin City Hospital Dermatology Feng Zhihong
Asia, HIV, children, AIDS drugs, resistance, osteoporosis, Suining
World AIDS Day, AIDS groups said publicly that TREAT Asia, Asian youth receiving HIV treatment in patients showing early signs of osteoporosis, only 5-year-old children on the AIDS drug resistance, as urged to give young HIV patients with more attention.
The findings remind people, though a growing number of HIV Asian patients are essential AIDS drugs, but they do not have improved drugs, including patients, including adults and children, continued lack of interest.
According to UNICEF, Asia about 16 million children infected with HIV. Among them, 57,000 children need treatment, but by the end of 2008 only 30,000 children receive treatment.
Researchers found the group, only 5-year-old children gradually began to AIDS drug resistance, may soon need to be improved, more expensive drugs, but they are not.
Person in charge of the group, said Dr. Annette Sohn, in their study population, about 14% of the patients are not first-line drugs, some of the children less than five years old has started second-line drugs.
Taking AIDS drugs are not punctual or not the law will lead to drug resistance. But in Asia, another reason is the lack of resistance in children with specific drug formulations.
Dr. Sohn said that in the HIV epidemic began we have committed errors in the management of HIV patients, children using adult formulations, Asian countries, children with no pediatric formulations.
Dr. Sohn said, health professionals and pharmaceutical manufacturers need to find ways to prepare the drug more powerful third-line drugs, available to children in poor countries. These drugs available in rich countries or the subsidies, but very expensive, sometimes in developing countries can not be. Or develop third-line drugs, then nothing the rest of the hospital will only patients, but doctors can not open the medicine to patients.
Of 4000 the group under the age of 23 AIDS patients in Asia's long-term studies have shown that low bone mineral density in patients with HIV-youth ratio is high, which is a precursor to osteoporosis.
To these patients about 16-year-olds to do a special X-ray and found that 15% of them have low bone mass. This is not normal, because the 16-year-olds should not be a low bone mass, low bone mass in HIV patients because of the body, including brain, bone, immune system effects.
Dr. Sohn is the HIV / AIDS in children's pediatrician, he thinks this may be due to some AIDS drugs, such as tenofovir, the toxic effects on bone.
The problem is not without one or both drugs, but to pay attention to their common side effects with any dose of study drug will not only inhibit the virus without producing toxicity, have the resources to monitor side effects, and there are ways to change in the production of side effects medicine.
The study included Thailand, Vietnam, Malaysia, Cambodia, Indonesia and India. TREAT Asia is the clinics, hospitals and research institutions working together to improve the therapeutic approach of networking groups.
